Pàgina inicial > Resultats de la cerca: Ponce, Santiago
  Consells de cerca
Cerca avançada
Cerca col·leccions:
Ordena'ls per: Mostrar els resultats: Format de visualizació:
Resultats globals: 3 registres trobats en 0.02 segons.
Articles, 3 registres trobats
Articles 3 registres trobats  
1.
11 p, 474.2 KB Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease / Socinski, Mark A. (Univeristy of Pittsburgh Cancer Institute) ; Kaye, Frederic J. (University of Florida College of Medicine) ; Spigel, David R. (Sarah Cannon Research Institute) ; Kudrik, Fred J. (South Carolina Oncology Associates) ; Ponce, Santiago (Hospital 12 de Octubre (Madrid)) ; Ellis, Peter M. (Juravinski Cancer Centre) ; Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ; Lorigan, Paul (University of Manchester/Christie NHS Foundation Trust) ; Gandhi, Leena (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ; Gutierrez, Martin E. (Holy Cross Hospital) ; Nepert, Dale (Clinical Development. ImmunoGen Inc) ; Corral, Jesus (Hospital 12 de Octubre (Madrid)) ; Ares, Luis Paz (Hospital 12 de Octubre (Madrid)) ; Universitat Autònoma de Barcelona
Lorvotuzumab mertansine (LM, IMGN901) is a CD56-targeting antibody-drug conjugate developed for tumor-selective delivery of the cytotoxic maytansinoid DM1. This phase 1/2 study evaluated the combination of LM with first-line carboplatin/etoposide chemotherapy in patients with extensive-disease small-cell lung cancer. [...]
2017 - 10.1016/j.cllc.2016.09.002
Clinical Lung Cancer, Vol. 18 Núm. 1 (january 2017) , p. 68-76.e2  
Registre complet - Creative Commons
2.
10 p, 666.8 KB Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain / Arriola, Edurne (Hospital del Mar (Barcelona, Catalunya)) ; García Gómez, Ramón (Hospital General Universitario Gregorio Marañón) ; Diz Taín, Pilar (Hospital Universitario de León) ; Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ; Martínez Aguillo, Maite (Complejo Hospitalario de Navarra) ; Valdivia, Javier (Hospital Universitario Virgen de las Nieves (Granada)) ; Paredes, Alfredo (Hospital de Donostia (Sant Sebastià, País Basc)) ; Sánchez-Torres, José Miguel (Hospital Universitario de la Princesa (Madrid)) ; Peralta Muñoz, Sergio (Hospital Universitari Sant Joan de Reus (Tarragona)) ; Barneto Aranda, Isidoro (Hospital Universitario Reina Sofía (Córdoba, Espanya)) ; Gutierrez, Vanesa (Hospital Regional Universitario Carlos Haya (Málaga)) ; Andrade Santiago, Jesús Manuel (Hospital Virgen de la Salud (Toledo)) ; Aparisi, Francisco (Hospital Virgen de los Lirios) ; Isla, Dolores (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ; Ponce, Santiago (Hospital 12 de Octubre (Madrid)) ; Vicente Baz, David (Hospital Universitario Virgen Macarena (Sevilla, Andalusia)) ; Artal, Ángel (Hospital Universitario Miguel Servet (Saragossa)) ; Amador, Mariluz (AstraZeneca) ; Provencio, Mariano (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ; Universitat Autònoma de Barcelona
Although the benefit of first-line epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors (TKIs) over chemotherapy has been demonstrated in several clinical trials, data from clinical practice is lacking and the optimal EGFR TKI to be used remains unclear. [...]
2018 - 10.1186/s12885-018-4004-7
BMC Cancer, Vol. 18 Núm. 1 (30 2018) , p. 106  
Registre complet - Creative Commons
3.
9 p, 801.8 KB PD-1 Blockade in Anaplastic Thyroid Carcinoma / Capdevila Castillón, Jaume (Vall d'Hebron Institut d'Oncologia) ; Wirth, Lori J. (Harvard Medical School) ; Ernst, Thomas (Universitätsklinikum Jena) ; Ponce Aix, Santiago (Hospital Universitario 12 de Octubre (Madrid)) ; Lin, Chia-Chi (National Taiwan University Hospital (Taipei, Taiwan)) ; Ramlau, Rodryg (Poznań University of Medical Sciences) ; Butler, Marcus O. (Princess Margaret Cancer Centre) ; Delord, Jean-Pierre (IUCT Oncopole) ; Gelderblom, Hans J (Leiden University Medical Center) ; Ascierto, Paolo A. (Istituto Nazionale Tumori IRCCS Fondazione G. Pascale) ; Fasolo, Angelica (San Raffaele Hospital) ; Führer, Dagmar (University Hospital Essen (Alemanya)) ; Hütter-Krönke, Marie Luise (University Hospital of Ulm (Alemanya)) ; Forde, Patrick M. (Sidney Kimmel Comprehensive Cancer Center) ; Wrona, Anna (Uniwersyteckie Centrum Kliniczne) ; Santoro, Armando (IRCCS Humanitas University) ; Sadow, Peter M. (Harvard Medical School) ; Szpakowski, Sebastian (Novartis Institutes for BioMedical Research) ; Wu, Hongqian (Novartis Pharmaceuticals) ; Bostel, Geraldine (Novartis Institutes for BioMedical Research) ; Faris, Jason (Novartis Institutes for BioMedical Research) ; Cameron, Scott (Novartis Institutes for BioMedical Research) ; Varga, Andreea (Gustave Roussy Cancer Campus) ; Taylor, Matthew (Oregon Health & Science University) ; Universitat Autònoma de Barcelona
Anaplastic thyroid carcinoma is an aggressive malignancy that is almost always fatal and lacks effective systemic treatment options for patients with BRAF -wild type disease. As part of a phase I/II study in patients with advanced/metastatic solid tumors, patients with anaplastic thyroid carcinoma were treated with spartalizumab, a humanized monoclonal antibody against the programmed death-1 (PD-1) receptor. [...]
2020 - 10.1200/JCO.19.02727
Journal of Clinical Oncology, Vol. 38 Núm. 23 (may 2020) , p. 2620-2627  
Registre complet - Creative Commons

Vegeu també: autors amb noms similars
1 Ponce, S
3 Ponce, S.
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.
Dipòsit Digital de Documents de la UAB :: Cerca :: Lliura :: Personalitza :: Ajuda
Powered by Invenio v1.1.6
Mantingut per ddd.bib@uab.cat  :: Metadades subjectes a:
Col·laborem